Skip to content
Screener

Denali Therapeutics Inc. DNLI Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$15.4B-739%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$92.7M+91.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$49M-141%
uniQure logo
uniQureQURE
$53.26M-27.1%
PTC Therapeutics logo
PTC TherapeuticsPTCT
-$93.74M+49.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$231.16M-405%

Other financials

Income statement

See full
Revenue$3.6M
Gross profit$3.5M
Operating income-$130.5M+3.3%
Net income-$127.6M-2.8%
EPS (diluted)-$0.68+5.6%

Balance sheet

See full
Cash & equivalents$204.6M+41.8%
Total debt$37.7M-21.4%
Total equity$835.2M-18.7%
Total assets$1.2B-0.7%

Cash flow

See full
Operating cash flow-$97.0M-28.8%
CapEx$805.0K-81.2%
Free cash flow-$97.8M-22.9%

Valuation

See full
Market cap$3.92B+88.3%
Enterprise value$3.76B+89.0%
P/S1,089×+1,084×

Profitability

See full
Operating margin-37,938%-37,986pp
Net margin-33,121.9%-33,159pp
FCF margin-31,736.3%-31,830pp

Returns & leverage

See full
Return on equity-54.9%+34.3pp
Debt / equity0.0×
Current ratio8.4×-1.9×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:08 PM EDT
Fiscal quarter
Q4 FY2026
Calendar quarter
Q4 2026
Accession
0001714899-26-000097
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Maturities and sales of marketable securities417,032323,965
Purchases of property and equipment(3,271)(9,356)
Cash paid to acquire finite-lived intangible asset(28,800)
Net cash provided by (used in) investing activities(9,618)176,683
Financing activities
Proceeds from underwriter exercising option to purchase common stock, net of issuance costs12,366
Proceeds from sale of revenue participation right200,000
Proceeds from exercise of awards under equity incentive plans21,7004,652

Item 1. Financial Statements (Unaudited)

FAQ

What is Denali Therapeutics Inc.'s investing cash flow?
Denali Therapeutics Inc. (DNLI) reported investing cash flow of -$104.08M in Q2 2026.
How has Denali Therapeutics Inc.'s investing cash flow changed year-over-year?
Denali Therapeutics Inc.'s investing cash flow decreased by 165.9% year-over-year, from $157.94M to -$104.08M.
What is the long-term trend for Denali Therapeutics Inc.'s investing cash flow?
Over 2 years (2021 to 2025), Denali Therapeutics Inc.'s investing cash flow has grown at a 243.6% compound annual growth rate (CAGR), from -$21.63M to $255.28M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Denali Therapeutics Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude